Increased motility and invasiveness of pancreatic cancer cells are associated with epithelial to mesenchymal transition (EMT). Snai1 and Slug are zinc-finger transcription factors that trigger this process by repressing E-cadherin and enhancing vimentin and N-cadherin protein expression. However, the mechanisms that regulate this activation in pancreatic tumors remain elusive. MUC1, a transmembrane mucin glycoprotein, is associated with the most invasive forms of pancreatic ductal adenocarcinomas (PDA). In this study, we show that over expression of MUC1 in pancreatic cancer cells triggers the molecular process of EMT, which translates to increased invasiveness and metastasis. EMT was significantly reduced when MUC1 was genetically deleted in a mouse model of PDA or when all seven tyrosines in the cytoplasmic tail of MUC1 were mutated to phenylalanine (mutated MUC1 CT). Using proteomics, RT-PCR and western blotting, we revealed a significant increase in vimentin, Slug and Snail expression with repression of E-Cadherin in MUC1-expressing cells compared with cells expressing the mutated MUC1 CT. In the cells that carried the mutated MUC1 CT, MUC1 failed to co-immunoprecipitate with b-catenin and translocate to the nucleus, thereby blocking transcription of the genes associated with EMT and metastasis. Thus, functional tyrosines are critical in stimulating the interactions between MUC1 and b-catenin and their nuclear translocation to initiate the process of EMT. This study signifies the oncogenic role of MUC1 CT and is the first to identify a direct role of the MUC1 in initiating EMT during pancreatic cancer. The data may have implications in future design of MUC1-targeted therapies for pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States (Chang et al., 2010) . This disease remains a major therapeutic challenge, as it is naturally resistant to current chemotherapy/radiation treatments. Poor prognosis has been attributed to delayed diagnosis, early vascular dissemination and metastases to distant organs, especially the liver and peritoneum (Burris et al., 1997) . One important insight came from the discovery that the increased motility and invasiveness of cancer cells are associated with epithelial to mesenchymal transition (EMT) (Nieto, 2002; Thiery, 2002) . In EMT, epithelial cells acquire fibroblast-like properties and show reduced intercellular adhesion and increased motility. This process is associated with the transcriptional repression and functional loss of E-cadherin (Nieto, 2002; Thiery, 2002) . Several transcription factors have been implicated in this repression, including the zinc-finger proteins of the Snail/Slug family (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002) , dEF1/ZEB1, SIP1 (Comijn et al., 2001) and the basic helix-loop-helix E12/E47 factor (Bolos et al., 2003) . Snail was shown to repress the expression of E-cadherin and induce EMT in several cancer cells (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002) . Although several factors such as TGF-b and the estrogen receptor were shown to regulate Snail transcription (Fujita et al., 2003; Peinado et al., 2003) , the mechanisms that modulate the function of Snail have remained largely elusive. Recently, dual regulation of Snail by glycogen synthase kinase 3-b-mediated phosphorylation has been implicated in EMT (Zhou et al., 2004) .
MUC1 is a transmembrane mucin glycoprotein that is overexpressed and aberrantly glycosylated in 490% of metastatic PDA (Lan et al., 1990) . Although elevated levels of MUC1 protein have been associated with higher metastasis and poor prognosis, its molecular role in metastasis remains unclear (Patton et al., 1995; Spicer et al., 1995; Schroeder et al., 2003; Tinder et al., 2008) . Multiple reports have appeared over the past decade demonstrating an incredible range of intracellular signaling functions associated with the 72-amino-acid residue of the MUC1 cytoplasmic tail (MUC1 CT), which is reviewed in (Hollingsworth and Swanson, 2004; Singh and Hollingsworth, 2006; Carson, 2008) . MUC1 CT is a target for several kinases, including z-chainassociated protein kinase of 70 kD (ZAP-70), the d-isoform of protein kinase C, glycogen synthase kinase 3-b and the tyrosine kinases c-Src and Lck (Mukherjee et al., 2005; Hattrup and Gendler, 2008; Kufe, 2008) . Phosphorylation of the tyrosine within the TDRSPYEKV sequence by c-Src and Lck stimulates interactions between MUC1 and b-catenin whereas phosphorylation of Ser by glycogen synthase kinase 3-b inhibits this interaction (Ren et al., 2002 (Ren et al., , 2006 . The same tyrosine residue is critically important for nuclear localization of MUC1, apparently because of the requirement for tyrosine phosphorylation to support the appropriate interactions necessary for intracellular trafficking. Binding to b-catenin appears to provide the signals required for movement of MUC1 to the nucleus in tumor cells (Carson, 2008) thereby influencing transcription through T-cell factor/lymphoid enhancer factor and/or other transcription factors (Hollingsworth and Swanson, 2004) .
We have generated human pancreatic cancer cell lines that express wild-type MUC1 or mutated MUC1 CT in which all seven tyrosines are mutated to phenylalanine. We have also generated mouse models of PDA that either express human MUC1 (Tinder et al., 2008) or genetically lack MUC1. Cell lines have been developed from these mice to study the oncogenic role of MUC1 in pancreatic cancer progression. In this study, we show that EMT and secondary metastasis were significantly reduced in PDA mice that lack MUC1 compared with PDA mice that express MUC1. In contrast, overexpression of MUC1 in both human and mouse pancreatic cancer cells initiated EMT by inducing the transcription factors Snail and Slug and repressing E-Cadherin, which lead to increased invasion and metastasis. Furthermore, mutating the tyrosines in MUC1 CT to phenylalanine completely blocked EMT and prevented metastasis. The data suggest direct oncogenic signaling through the tyrosines of MUC1 CT in the induction of EMT and metastasis during pancreatic cancer.
Results
Lower incidence of metastasis in PDA.MUC1KO mice compared with PDA.MUC1 mice: evidence of EMT in PDA.MUC1 tumors PDA.MUC1 and PDA.MUC1KO mice were killed at B36-40 weeks of age when all mice had primary pancreatic tumors. When organs were evaluated for macroscopic lesions, 60% (8/13 mice) of the PDA. MUC1 mice developed lung metastasis with B40% (5/13) developing liver and B20% (3/13) developing peritoneum metastasis (Figure 1b ). This was in contrast to PDA.MUC1KO mice wherein only 1 out of 10 mice developed metastasis in all three organs. To investigate the mechanism by which MUC1 initiated higher metastasis, we evaluated whether MUC1 has a role in activating the EMT-associated proteins in the primary tumors. Tumor lysates from PDA.MUC1 and PDA. MUC1KO tumors (n ¼ 5) were analyzed by proteomics. Several proteins were differentially expressed; however, the most notable differences were in the levels of vimentin and E-Cadherin. In the PDA.MUC1 tumors, there was a significant fivefold increase in vimentin with a concurrent decrease in E-Cadherin (Figures 1c and d) .
In contrast, the pattern was completely reversed in the PDA.MUC1KO tumors with significantly higher (fourfold) levels of E-Cadherin and lower levels of vimentin (Figures 1c and d) . The data were the first indication of possible induction of EMT in the MUC1-expressing tumors. Repression of E-Cadherin and induction of vimentin in the PDA.MUC1 tumors directly correlated with increased metastasis in the PDA.MUC1 mice.
MUC1 promotes induction of mesenchymal markers and functionally enhances the invasive capacity of pancreatic cancer cells in vitro
To further confirm the role of MUC1 in EMT, KCKO and KCM cell lines were generated from the PDA.MUC1KO and PDA.MUC1 mice, respectively. MUC1 expression was confirmed by western blotting (Figure 1e ) using MUC1 tandem repeat (TR, B27.29) and MUC1 CT (CT2) antibodies with high expression detected in KCM and no expression in KCKO cells (Figure 1e ). B27.29 antibody detects the high-molecularweight extracellular domain (4200 kDa) and CT2 detects the low-molecular-weight CT domain (30 kDa). Both cell lines were subjected to an in vitro invasion assay, results of which showed significantly higher invasion index of the KCM compared with the KCKO cells (Po0.01, Figure 1f ), confirming MUC1 as the major contributor of increased motility and invasiveness. Furthermore, presence of MUC1 in KCM tumors clearly repressed E-Cadherin expression ( Figure 1d ) and induced expression of transcription factors and proteins associated with the mesenchymal phenotype. These included Snail, Slug, N-cadherin and vimentin ( Figure 1g ), which potentially contributed to the contact inhibition and high invasion in vitro and in vivo (Figures 1b and f). Lastly, KCM cells expressed higher levels of vascular endothelial growth factor (VEGF) compared with KCKO cells (Figure 1g ), another indicator of highly metastatic phenotype. Thus, we hypothesized that MUC1 induces EMT and initiates invasion in mouse pancreatic cancer cells.
Overexpression of MUC1 in human pancreatic cancer cells promotes EMT and induces invasion: role of tyrosines in the MUC1 CT
To further test our hypothesis and delineate the potential mechanism, we stably infected human pancreatic cancer cell lines, BxPC3 and Su86.86 with full length MUC1 or mutated MUC1 CT. Cells expressing full length MUC1 were designated BxPC3 MUC1 and Su86.86.MUC1 whereas cells expressing mutant MUC1 CT were designated BxPC3.Y0 and Su86.86.Y0. Cells infected with an empty vector containing the neomycin resistance gene were used as controls and designated BxPC3.Neo and Su86.86.Neo. The only difference between MUC1 and Y0 constructs was that in Y0 construct, all seven tyrosines in MUC1 CT were replaced by phenylalanine. Expression of MUC1 was confirmed in both cell lines by western blotting (Figures 2a-d ) using both the B27.29 and CT2 antibodies. The small shift in electrophoretic mobility noted in the Y0 cell lysate relative to MUC1 cells likely reflects a decrease in phosphorylation due to the mutations of the tyrosine residues in the Y0 cells (Figures 2b and d ). An in vitro invasion assay showed significantly higher invasion index for MUC1 cells as compared with Y0 and Neo cells (Po0.01, Figures 2e and f). These data suggest that the increased invasiveness of the MUC1-expressing cells may be attributed to the tyrosines in the MUC1 CT. To substantiate the role of the MUC1 CT tyrosines as an inducer of EMT, real-time PCR arrays were used to explore transcription of 72 genes implicated in EMT and metastasis. Genes whose transcription was altered by at least twofold compared with Neo cells were considered significant. Several genes associated with tight junctions and epithelial phenotype were significantly reduced in BxPC3 MUC1 compared with the Neo cells. These included tight junction proteins 1 and 3, occludin, laminin a5, b-and d-catenin, claudin and E-cadherin ( Figure 2g ). In contrast, there was no such change in the Y0 cells ( Figure 2g ). Conversely, genes associated with the mesenchymal phenotype and invasion were significantly increased in the BxPC3 MUC1 and decreased in the Y0 cells compared with Neo cells. These included vimentin, Twist, Slug, Snail and goosecoid ( Figure 2h ). Both functional and molecular studies indicate that MUC1 initiates the process of EMT via signaling through the tyrosines in its CT and that no external factor is necessary to stimulate these changes. Loss of epithelial and gain of mesenchymal markers in MUC1, but not in Y0 cells directly correspond to their transcription of metastasis-associated genes At the protein level, gain of mesenchymal markers such as Slug, Snail and vimentin and loss of E-cadherin expression was apparent in the MUC1 cells ( Figures  3a-d ). These alterations in protein expression compared with Neo cells were not detected in the Y0 cells, implicating the importance of the tyrosines for effective oncogenic signaling and induction of EMT ( Figures  3a-d ). Downregulation of E-cadherin was further confirmed by confocal microscopy in BXPC3 MUC1 but not in the Y0 cells ( Figure 3e ). It is well established that Snail represses the expression of E-cadherin to induce EMT in several cancer cells (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002) . Thus, the data clearly suggest that MUC1 has a critical role in inducing EMT in human pancreatic cancer cell lines via signaling through its CT tyrosines. Furthermore, genes associated with metastasis and angiogenesis such as VEGF, MMP-9, 3, and 2 and IL-6R were significantly increased in BxPC3 MUC1, but not in the Y0 cells compared with Neo controls (Figure 3f ). Therefore, we propose that without functional tyrosines in MUC1 CT, EMT and metastasis may be blocked in human pancreatic cancer cells.
Circulating tumor cells detected in mice bearing the BxPC3 MUC1 but not Neo or Y0 tumors
To test tumor growth and metastasis in vivo, BxPC3 MUC1, Y0 and Neo cells were subcutaneously injected into nude mice. All cells formed tumors within 15 days post injection, with tumor growth being significantly higher in BxPC3 MUC1 versus Y0 and Neo tumors (Figure 4a; *P ¼ 0.02-0.05). BxPC3 MUC1 and Y0 tumors expressed high levels of MUC1 whereas Neo tumors expressed negligible amounts of MUC1 ( Figure 4b ). We were unable to detect gross metastatic lesions from these tumors; therefore, we evaluated levels of circulating tumor cells in the blood of these mice. Within 2 weeks of culture, we were able to detect colonies of tumor cells in the blood collected from BxPC3 MUC1 but not from Neo or Y0 tumor-bearing mice (Figure 4c ). The data signify the role of MUC1 CT tyrosines during pancreatic cancer growth and extravasation of the cells into the blood stream for future metastasis. Genes whose transcription was altered by at least twofold or more were considered significant. Average fold change is shown from three separate experiments. All experiments were repeated three times with a R-value (correlation coefficient) of 40.98. Clones from three independent infections were analyzed with similar results.
Detection of EMT in vivo in BxPC3 MUC1 tumors
Protein lysates from the tumors were analyzed for the epithelial and mesenchymal markers. Similar to the in vitro data in Figure 3 , the BxPC3 MUC1 tumor lysate showed downregulation of E-Cadherin ( Figure 4d ) and upregulation of Slug, Snail and vimentin ( Figure 4e ) clearly indicating the initiation of EMT in vivo. This process was completely abrogated when the tyrosines were mutated even though high levels of MUC1 protein was being expressed in the Y0 tumors ( Figure 4b ).
Significantly higher levels of prometastatic and proangiogenic growth factors in the BXPC3 MUC1 tumor microenvironment compared with Y0 or Neo tumors To determine the effect of EMT on the tumor microenvironment itself, we tested the protein levels of some of the known mediators of metastasis and angiogenesis in the tumor lysates using the Ray Biotech protein array kit (Ray Biotech, Norcross, GA, USA). Twofold or more increase was considered significant and is represented (Figure 4f ). Significant increases in levels of circulating VEGF (10-fold), insulin-like growth factor-1 (twofold), interleukin-6 (threefold) and its receptor (interleukin-6, 2.2-fold), stem cell factor (2.5 fold), P-selectin (20-fold) and epidermal growth factor (2.8-fold) were observed in the BxPC3 MUC1 tumors compared with the Neo and Y0 tumors. VEGF expression was also determined by immunohistochemistry in the tumor sections with high levels detected in the BxPC3 MUC1 tumors versus Neo and Y0 tumors (Figure 4g ). Thus, BxPC3 MUC1-xenografted tumors exhibited an aggressive phenotype consistent with the human tumors that express high MUC1. This included loss of E-cadherin, induction of vimentin and upregulation of metastatic and angiogenic factors. It is striking that simply abrogating the signal transduction events by mutating the seven tyrosines can completely reverse the process of EMT and significantly alter the tumor microenvironment, subsequently leading to a less aggressive, less metastatic and less angiogenic phenotype.
MUC1 interacts with b-catenin and translocates to the nucleus in the BxPC3 MUC1 but not in the Y0 cells To delineate the underlying mechanism by which the Y0 tumors circumvent EMT, we tested the nuclear localization of MUC1 CT and b-catenin in the MUC1 and Y0 cells. It is known that tyrosine residues in MUC1 CT are critically important for nuclear localization of MUC1 CT and b-catenin (Hollingsworth and Swanson, 2004) . Although b-catenin was present in the nuclear extracts of both cells, the levels were significantly higher in BxPC3 MUC1 cells compared with the Y0 cells ( Figure 5a ). Similar results were obtained with the KCM and KCKO cells wherein higher levels of bcatenin were detected in the nuclear extract of the KCM versus the KCKO cells ( Figure 4b ). More importantly, although both BxPC3 MUC1 and Y0 cells contained equal levels of MUC1 (Figure 3a) , there was no detectable MUC1 CT in the nuclear extract of the Y0 cells while high levels was detected in the BxPC3 MUC1 cells (Figure 5a ). The results were substantiated in Su86.86 MUC1 and Y0 cells (Figure 5c ). The data clearly suggest that signaling through the tyrosines is critically important for efficient nuclear translocation of MUC1 CT and b-catenin. Purity of the nuclear extract was confirmed by the presence of lamin and the absence of IKK (Figures 5a-c) .
As tyrosine phosphorylation is required for MUC1 to bind b-catenin and translocate to the nucleus, we examined if b-catenin and MUC1 co-immunoprecipitated in these cells. b-catenin interacted with MUC1 only in the BxPC3 MUC1 cells but minimally in the Y0 cells (Figure 5d ). The co-immunoprecipitation of b-catenin and MUC1 was confirmed in the KCM and KCKO cells and in the Su86.86 cells (Figures 5e and f) . Thus, we confirm that binding of MUC1 to b-catenin appears to provide the signal required for movement of MUC1 to the nucleus and that the tyrosines in MUC1 CT have to be functional for the two proteins to interact.
Discussion
Although it has been known for decades that MUC1 is aberrantly overexpressed in greater than 95% of metastatic PDA and is associated with poor prognosis, its precise role has remained obscure. We show for the first time in both mouse and human pancreatic tumors that (1) overexpression of MUC1 initiates the process of EMT and augments metastasis and (2) lack of tyrosines in the CT of MUC1 abrogates this process. The first evidence of EMT came from the proteomics data showing repression of E-cadherin and induction of vimentin expression in the PDA.MUC1 tumors when compared with the PDA.MUC1KO tumors. This correlated with significantly higher incidence of secondary metastasis in PDA.MUC1 mice as compared with the PDA.MUC1KO mice. The PDA mice are unique in that the pancreatic tumors arise spontaneously in an appropriate tissue background, within a suitable stromal and hormonal milieu, and in the context of a viable immune system (Hingorani et al., 2003; Tinder et al., 2008; Mukherjee et al., 2009 ). The tumor progression and the histopathology of the tumors in the PDA mice mimic the human disease with the initial development of pancreatic intraepithelial neoplastic lesions progressing to carcinoma in-situ and invasive adenocarcinoma. The process of EMT and increased invasiveness in MUC1-expressing pancreatic tumors was confirmed in cell lines generated from the PDA mice and validated in two human pancreatic cell lines. The underlying molecular mechanism in all cell lines pointed to the induction of transcription factors, Snail, and Slug, which stimulated the expression of vimentin and repressed E-cadherin expression. E-cadherin has a key role in the establishment and maintenance of adherent junctions and loss of the same results in contact inhibition and cell motility. Interestingly, the molecular process of EMT was completely abrogated when all seven tyrosines in the CT of MUC1 were mutated to phenylalanine. Note that the cytoplasmic tail of MUC1 Y0 shows a shift in electrophoretic mobility relative to MUC1 WT; this likely reflects a decrease in phosphorylation due to mutation of the tyrosine residues and therefore change in the overall charge. This has been previously reported in other cell types (Thompson et al., 2006) . We do not believe that the change in the electrophoretic mobility is due to size as the D between seven tyrosines and seven phenylalanines is B47 daltons. Recent evidence shows that the phosphorylation of the tyrosines in the MUC1 CT is critical for the binding of b-catenin to MUC1 CT and that the MUC1 CT-b-catenin complex can be translocated to the nucleus to render its oncogenic signal (Wen et al., 2003) . We show that lack of tyrosines in the MUC1 CT regulates the interaction between MUC1 CT with b-catenin, and therefore its efficient in translocation to the nucleus ( Figure 5 ). It is also known that b-catenin binds to the SXXXXXSSL motif in the CT of MUC1 (Yamamoto et al., 1997) and changes in tyrosine phosphorylation of MUC1 CT correlated with differences in cell adhesion (Yamamoto et al., 1997; Quin and McGuckin, 2000) . Thus, we can speculate that the underlying mechanism for EMT might be the requirement of the tyrosines adjacent to the b-catenin-binding domain (possibly at the TDRSPYEKV site) to be phosphorylated. The c-Src and d-isoform of protein kinase C have been shown to phosphorylate the tyrosines at that site and increase the interaction between b-catenin and MUC1 (Li and Kufe, 2001; Ren et al., 2002) . We therefore propose that MUC1 may directly influence the transcriptional co-activator status of b-catenin, and upregulate several genes that are associated with EMT such as Snail, Slug, Twist, vimentin and goosecoid (Figure 2d) , possibly through interactions with T-cell factor/lymphoid enhancer factor and/or other transcription factors. Snail in turn represses E-cadherin message and protein levels in Non-specific pull down was not detected using an IgG control antibody (data not shown). Note: Neo cells were not included in the data as they express minimal levels of endogenous MUC1 and we found little to no b-catenin or MUC1 CT in the nucleus (data not shown). (Figures 1-4) , perhaps through direct binding to the three E-boxes in the E-cadherin promoter (Guaita et al., 2002) . E-cadherin has a key role in the establishment and maintenance of adherence junctions, repression of which leads to downregulation of tight junction proteins 1 and 3, occludin, laminin a5, and b-and d-catenins (Figure 2c ). Dissolution of pancreatic epithelial cell junctions is hence brought about by a concerted activation of mesenchymal proteins and repression of epithelial proteins in vitro and in vivo, leading to EMT and metastasis exemplified by the presence of circulating tumor cells in BxPC3 MUC1 tumors (Figure 4c ) and enhanced metastasis in the PDA.MUC1 mice (Figure 1b) .
MUC1-expressing cells
These molecular changes lead to an in vivo microenvironment favoring increased angiogenic and proinflammatory cytokines in the MUC1 tumors (Figures 4f  and g) , leading to increased metastasis. The glycoprotein P-selectin, an adhesion molecule involved in the initiation of inflammatory process and induction of interleukin-6 and its receptors (Kaikita et al., 1995; Dymicka-Piekarska et al., 2007) was increased by 20-fold in MUC1 versus Neo tumors (Figure 4f ). VEGF, a potent inducer of angiogenesis and promoter of tumor progression (Justinger et al., 2008) was increased by 10-fold in the MUC1 tumors (Figure 4f) . Lastly, stem cell factor, epidermal growth factor and insulin-like growth factor-1, factors known to induce growth and proliferation in pancreatic cancer cells (Bardeesy and DePinho, 2002; Mroczko et al., 2005; Wolpin et al., 2007) were increased by 2-3-fold in MUC1 tumors (Figure 4f ). Thus, it is indeed striking that the significant induction of these factors in the MUC1 tumors was completely abrogated when the tyrosines in MUC1 CT were deemed nonfunctional (Figure 4f ). This once again signifies the critical requirement of the MUC1 CT tyrosines in pancreatic cancer oncogenesis and metastasis.
The regulation of MUC1 CT phosphorylation and parameters that affect its association with b-catenin are not fully understood, although interaction of MUC1 with ErbB1 (Schroeder et al., 2001) has been shown to enhance the binding between c-src, b-catenin and MUC1 (Hollingsworth and Swanson, 2004 ) and increase ERK1/2 phosphorylation and NFkB activation (Schroeder et al., 2001; Thompson et al., 2006) . Preliminary data from our laboratory show that the active form of NFkB-p65 subunit translocation to the nucleus is negligible in the Y0 cells compared with the MUC1 cells (unpublished data).
Our study exemplifies the functional consequences (EMT and metastasis) of signaling through MUC1 CT, and for the first time delineates the role of this protein in a unique mouse model of PDA that lacks MUC1. The data define the role of MUC1 signaling (through its CT tyrosines) in the initiation of EMT perhaps by b-catenin-MUC1 interaction and translocation to the nucleus, leading to activation of the EMT-associated transcription factors Snail and Slug. This in turn enables the tumors to acquire a highly aggressive phenotype creating a prometastatic microenvironment in vivo. Future studies will focus on identifying the particular tyrosine/s within MUC1 CT and determining whether inhibiting its phosphorylation using small molecule kinase inhibitors may lead to a novel treatment modality for pancreatic cancer.
Materials and methods
Mouse model PDA mice were generated in our laboratory on the C57BL/6 background by mating the P48-Cre with the LSL-KRAS G12D mice (Hingorani et al., 2003) and further mated to the MUC1.Tg mice to generate PDA.MUC1 mice (Tinder et al., 2008; Mukherjee et al., 2009) or to the MUC1KO mice to generate PDA.MUC1KO mice (Figure 1a ). Primary tumors were dissociated using collagenase IV (Worthington Biochemical Corp, Lakewood, NJ, USA) and several lines of cells were generated in our laboratory. These cells are designated KCKO for cells lacking MUC1 and KCM for cells expressing human MUC1.
Invasion assays
Cells were serum-starved for 24 h before plating for the invasion assay. Cells in serum-free media (50 000 cells) were plated over transwell inserts (BD Biosciences, San Jose, CA, USA) precoated with reduced growth factor matrigel, and were permitted to invade toward the serum contained in the bottom chamber for 48 h. Percent invasion was calculated as absorbance of samples/absorbance of controls Â 100.
Western blots and antibodies
Equal quantities of tumor lysate were loaded on SDS-PAGE gels. MUC1 CT antibody CT2, was made in Mayo Clinic Immunology Core (Schroeder et al., 2001) . MUC1 TR (B27.29) antibody was acquired from Biomira Inc. (Edmonton, Alberta, Canada). All other antibodies (Snail, Slug, N-cadherin, vimentin, VEGF, E-cadherin, b-catenin and bactin) were purchased from Santa Cruz Biotechnology, (Santa Cruz, CA, USA) and were used according to manufacturer's recommendations. Co-immunoprecipitation using CT2 (5ml.) and b-catenin (5ml.) was carried out as previously reported (Al Masri and Gendler, 2005) using 1 mg of protein lysate prepared in 1% Brij buffer followed by denaturing western blotting.
Cloning of MUC1 WT and MUC1 Y0 vectors MUC1 Y0 was created using the Quick Change mutagenesis kit (Stratagene, La Jolla, CA, USA) (Thompson et al., 2006) . Briefly, primers based on the MUC1 sequence were designed containing single-base alterations resulting in mutation of the tyrosine residues (Y) in MUC1 CT to phenylalanine (F) as shown schematically.
Successful mutations were confirmed with DNA sequencing. MUC1 Y0 and MUC1 WT were cloned into the pLNCX.1 vector consisting of the neomycin resistance gene for retroviral infection. Note: cells designated as BxPC3 MUC1 or Su89.86.MUC1 represents cells expressing full length MUC1 that consists of the extracellular domain, the transmembrane domain and wild-type cytoplasmic tail domain. Cells designated as BxPC3.Y0 or Su89.86. Y0 represents cells expressing full length MUC1 that consists of the extracellular domain, the transmembrane domain and mutant cytoplasmic tail domain in which only the seven tyrosines are replaced by phenylalanine. BxPC3.Neo and Su86.86.Neo represents cells that only express the empty vector and therefore represents the endogenous levels of MUC1 in these cells.
Cell culture and retroviral infection
BxPC3 cells and Su86.86 (American Type Culture Collection, Manassas, VA, USA) are two human pancreatic cancer cell lines that express very little endogenous MUC1. For retroviral infection, GP2-293 packaging cells (stably expressing the gag and pol proteins) were co-transfected with the full length MUC1 construct or the Y0 construct or an empty vector expressing the VSV-G envelope protein as previously described (Thompson et al., 2006) . Cells were selected with 0.5 mg/ml G418, beginning 48 h post infection. Three independent infections of the constructs were carried out with similar results. Expression of the constructs was stable throughout the span of experiments. Cells infected with vector alone were used as control and designated Neo. For MUC1 and Y0-infected cells, MUC1 þ ve cells were sorted using the FACSAria (BD Biosciences). For Neo-infected cells, MUC1-ve cells were sorted.
Confocal microscopy
Cells were plated on chamber slides and grown to the desired confluency. Cells were washed, fixed in À20 1C ethanol, permeabilized with 0.5% Tween 20 and stained with E-cadherin antibody. Nuclei were stained with To-pro-3 (Invitrogen, Carson City, CA, USA). Pictures were taken at Â 400 using a confocal microscopy (Carl Zeiss International, Thornwood, NY, USA).
Real-time PCR in the Taqman low-density custom made array format
Total RNA was extracted according to standard protocol using the Qiagen RNeasy mini-kit protocol (Invitrogen). Complementary DNA was constructed using TaqMan Reverse Transcription cDNA kit from Applied Bioscience (Foster City, CA, USA). Each low-density custom array card was configured for 72 different genes in triplicates. The SDS2.2 software (Carlsbad, CA, USA) was used for qualitative analysis. Arrays were performed independently at least three times for each cell line; values were obtained for the threshold cycle (Ct) for each gene and normalized using the average of four housekeeping genes on the same array (HPRT1, RPL13A, GAPDH, ACTB). Change (DCt) between Neo, MUC1 and Y0 was found by: DCt ¼ Ct (MUC1 or Y0)ÀCt (neo) and fold change by: fold change ¼ 2(ÀDCt). Values are provided as fold change.
Isolation of nuclear protein
Cells were washed in cold phosphate buffered saline and then resuspended in buffer A (10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid and 0.1% Nonidet-P40) on ice for 20 min. Lysates were spun at 6000 r.p.m., 1 min, 4 1C and the resulting pellets were washed twice in phosphate buffered saline before sonication in buffer B (20 mM HEPES pH 7.9, 25% glycerol, 400mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol) to obtain the nuclear fraction, which was then spun at 13 000 r.p.m. for 20 min, 4 1C, for western blot analysis using CT2 and b-catenin antibodies.
In vivo tumor growth Two-month old nude mice were injected with 5x10 6 tumor cells into the flank of the mice. Tumors were allowed to grow for 2 months. Mice were palpated every second day starting at 7 days post tumor injection until sacrifice. Tumor weight was calculated according to the following formula: grams ¼ (length in centimeters Â (width) 2 )/2 (Simpson-Herren and Lloyd, 1970) . On killing the mice, the tumor portions were prepared for lysates and fixed for immunohistochemistry.
Immunohistochemistry
Tumor sections were formalin fixed and paraffin embedded blocks were prepared by the Histology Core at The Mayo Clinic and 4-micron thick sections were cut for immunostaining. VEGF expression was determined using the antibodies (Santa Cruz Biotechnologies) at 1:50 dilution followed by the appropriate secondary antibody (1:100 dilution, DAKO, Carpenteria, CA, USA). Sections were developed using 3,3 0diaminobenzidine as the chromogen and hematoxylin as the counterstain. Slides were examined under light microscopy and pictures taken at Â 400 magnification.
Isolation of viable circulating human pancreatic cancer cells
Blood samples (0.5-1.0 ml) were obtained by cardiac puncture from individual tumor-bearing animals using heparin as the anticoagulant and processed immediately. Erythrocyte-free nucleated cell fractions were obtained using the RBC lysis buffer (Stemcell Technologies, Inc., Vancouver, British Columbia, Canada). This fraction was immediately expanded in culture in Dulbecco's modified Eagle's medium as previously described (Glinskii et al., 2003) .
Protein array
Tumor lysates were analyzed using the RayBio Custom protein array kit (RayBiotech, Norcross, GA, USA). Assay was conducted according to the manufacturer's instructions (Das Roy et al., 2009) . Chemiluminescence was detected using a EpiChemi3 Darkroom imaging system and LabWorks densitometry software (UVP Bioimaging, Upland, CA, USA). Data were corrected for background signal and normalized to positive controls using RayBio Analysis Tool software.
Proteomics
For the electrophoretic separation of each sample, 30 mg of protein was loaded on a 10% bis-Tris NuPAGE gel (Invitrogen) and proteomic analysis conducted as previously reported (Hwang et al., 2006) . A Nano Acuity UPLC system connected to an LTQ-Orbitrap hybrid MS system (Thermo Fisher, Pittsburg, PA, USA) with Nanospray interface was used. Data were acquired using Xcalibur and searched by Bioworks software (Thermo Fisher) using IPI mouse v.3.18 fasta database. Search results were entered into Scaffold software (Proteome Software, Portland, OR, USA) for compilation, normalization and comparison of spectral counts. Data sets were imported into R program (www.r-project.org) for statistical computing.
Statistical analysis
Statistical analysis was performed with SPSS 10 software (IBM Corporation, Somers, NY, USA). P-values were generated using the one-way analysis of variance and significance was confirmed using the Duncan and Student-Newman-Keul test. Values were considered significant if Po0.05.
